



**BioLight Sciences Ltd.**

("The Company")

\_\_\_ May 2026

To:  
Tel Aviv Stock Exchange Ltd.  
[www.tase.co.il](http://www.tase.co.il)

To:  
Israel Securities Authority  
[www.isa.gov.il](http://www.isa.gov.il)

To whom this may concern,

**Re: DiagnosTear – Engaging in an Exclusive License Agreement for New Technology**

Further to Section 4.2.13.4 of Part A of the Company's 2025 Annual Report<sup>1</sup>, the Company is pleased to announce that DiagnosTear Ltd.<sup>2</sup> ("Diagnostear") has entered into an agreement to obtain an exclusive license for the use and commercialization of a technology jointly developed by Sheba Medical Center and Tel Aviv University, currently known as "CLARIFY". CLARIFY is an imaging platform designed to perform blood counts and analyze blood related parameters directly through the eye, using noninvasive imaging of blood vessels on the surface of the eye (the "**Technology**" and the "**License Agreement**"). The technology is currently at an early stage following proof of concept in humans for the measurement of certain blood parameters.

Under the terms of the License Agreement signed with Sheba Impact, the technology transfer company of Sheba Medical Center, and Ramot, the technology transfer company of Tel Aviv University (together, the "**Commercialization Companies**"), DiagnosTear will pay royalties based on net sales of products developed using the technology, as well as a percentage of sublicense revenues, if any<sup>3</sup>.

As conveyed to the Company, the signing of the license agreement is part of DiagnosTear's efforts and initiatives to expand its areas of activity and become a multi-product company focused on point of care diagnostics for clinics and optical centers.

---

<sup>1</sup> As published on March 15, 2026 (Reference No. 2026-01-022732), which is incorporated herein by reference.

<sup>2</sup> Owned 100% by the Company's subsidiary, DiagnosTear Technologies Inc., which is publicly traded on the Canadian Securities Exchange (CSE) and the Frankfurt Stock Exchange (FSE), and in which the Company holds approximately 44%.

<sup>3</sup> Beginning in 2029, DiagnosTear will also be subject to annual license fees in a non material amount, which may be offset against royalties.



**Forward Looking Statement:**

The information and details included in this report regarding the receipt of regulatory approvals for products based on the technology (if obtained), as well as royalties and/or revenues from sales by DiagnosTear of products developed using the technology, together with forecasts, timelines, estimates and/or plans of the Company and/or DiagnosTear in connection therewith, constitute “forward looking information” as defined in the Israeli Securities Law, 1968. Such information involves significant uncertainty and is based, among other things, on third party factors and numerous variables beyond the Company’s and/or DiagnosTear’s control. Therefore, actual results may differ materially from those anticipated, estimated, or initially expected.

Sincerely,  
BioLight Life Sciences Ltd.

Approved for publication by:  
Yaacov Michlin, CEO  
Karin Gurevitz, VP and General Counsel